✦ LIBER ✦

Supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial—Rationale and design

✍ Scribed by Sakata, Yasuhiko; Nochioka, Kotaro; Miura, Masanobu; Takada, Tsuyoshi; Tadaki, Soichiro; Miyata, Satoshi; Shiba, Nobuyuki; Shimokawa, Hiroaki

Book ID: 123275159
Publisher: Elsevier
Year: 2013
Tongue: Japanese
Weight: 715 KB
Volume: 62
Category: Article
ISSN: 0914-5087
DOI: 10.1016/j.jjcc.2013.02.011

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rationale and design of the valsartan he

Rationale and design of the valsartan heart failure trial: A large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure

✍ Jay N. Cohn; Gianni Tognoni; Robert D. Glazer; Dirk Spormann; Allen Hester 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 576 KB

Dual angiotensin receptor and neprilysin

Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact

✍ McMurray, John J. V.; Packer, Milton; Desai, Akshay S.; Gong, Jim; Lefkowitz, Ma 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 305 KB

Review finds combining angiotensin recep

Review finds combining angiotensin receptor blockers with ACE inhibitors in heart failure may only benefit people with contraindications to β blockers: Abstracted from: Dimopoulos K, Salukhe TV, Coats AJ, et al. Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker). Int J Cardiol 2004; 93(2–3): 105–11.

📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 126 KB

Rationale, design, and baseline characte

Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): A randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure

✍ Fox, Kim; Ford, Ian; Steg, Philippe Gabriel; Tardif, Jean-Claude; Tendera, Micha 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 459 KB